JP4173549B2 - コアグラーゼ陰性ブドウ球菌に由来する、新規フィブリノーゲン結合たん白質 - Google Patents

コアグラーゼ陰性ブドウ球菌に由来する、新規フィブリノーゲン結合たん白質 Download PDF

Info

Publication number
JP4173549B2
JP4173549B2 JP50281998A JP50281998A JP4173549B2 JP 4173549 B2 JP4173549 B2 JP 4173549B2 JP 50281998 A JP50281998 A JP 50281998A JP 50281998 A JP50281998 A JP 50281998A JP 4173549 B2 JP4173549 B2 JP 4173549B2
Authority
JP
Japan
Prior art keywords
protein
polypeptide
fibrinogen
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP50281998A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001503609A (ja
JP2001503609A5 (enExample
Inventor
グス・ベンクト
ニルソン・マルティン
フリクベルク・ラルス
フロック・ヤン―イングマール
リンドベルク・マルティン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2001503609A publication Critical patent/JP2001503609A/ja
Publication of JP2001503609A5 publication Critical patent/JP2001503609A5/ja
Application granted granted Critical
Publication of JP4173549B2 publication Critical patent/JP4173549B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP50281998A 1996-06-20 1997-06-18 コアグラーゼ陰性ブドウ球菌に由来する、新規フィブリノーゲン結合たん白質 Expired - Fee Related JP4173549B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9602496A SE9602496D0 (sv) 1996-06-20 1996-06-20 Method and means for producing a fibrinogen binding protein and its use in biotechnology
SE9602496-3 1996-06-20
PCT/SE1997/001091 WO1997048727A1 (en) 1996-06-20 1997-06-18 New fibrinogen binding protein originating from coagulase-negative staphylococcus

Publications (3)

Publication Number Publication Date
JP2001503609A JP2001503609A (ja) 2001-03-21
JP2001503609A5 JP2001503609A5 (enExample) 2005-02-10
JP4173549B2 true JP4173549B2 (ja) 2008-10-29

Family

ID=20403140

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50281998A Expired - Fee Related JP4173549B2 (ja) 1996-06-20 1997-06-18 コアグラーゼ陰性ブドウ球菌に由来する、新規フィブリノーゲン結合たん白質

Country Status (10)

Country Link
US (2) US6733758B1 (enExample)
EP (1) EP0922056B1 (enExample)
JP (1) JP4173549B2 (enExample)
AT (1) ATE316979T1 (enExample)
AU (1) AU3282597A (enExample)
CA (1) CA2294433A1 (enExample)
DE (1) DE69735207T2 (enExample)
ES (1) ES2258280T3 (enExample)
SE (1) SE9602496D0 (enExample)
WO (1) WO1997048727A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6685943B1 (en) 1997-01-21 2004-02-03 The Texas A&M University System Fibronectin binding protein compositions and methods of use
US6380370B1 (en) * 1997-08-14 2002-04-30 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
AU1537699A (en) * 1997-11-26 1999-06-15 Bioresearch Ireland a division of Eolas - The Irish Science and Technology Agency Extracellular matrix-binding proteins from (staphylococcus aureus)
WO2000012131A1 (en) * 1998-08-31 2000-03-09 Inhibitex, Inc. Multicomponent vaccines
US6635473B1 (en) * 1998-08-31 2003-10-21 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Polypeptides and polynucleotides from coagulase-negative staphylococci
CA2341177A1 (en) * 1998-08-31 2000-03-09 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
US6692739B1 (en) 1998-08-31 2004-02-17 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
US6703025B1 (en) 1998-08-31 2004-03-09 Inhibitex, Inc. Multicomponent vaccines
US20040038327A1 (en) * 1999-08-31 2004-02-26 Foster Timothy J. Antibodies to polypeptides from coagulase-negative staphylococci
EP2320233A1 (en) 2001-06-15 2011-05-11 Inhibitex, Inc. Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and staphylococcus aureus
CA2478029A1 (en) * 2002-03-05 2003-09-18 Inhibitex, Inc. Monoclonal and polyclonal antibodies recognizing coagulase-negative staphylococcal proteins
CA2517439C (en) 2003-03-07 2013-07-23 Wyeth Holdings Corporation Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
ES2730275T3 (es) 2004-09-22 2019-11-11 Glaxosmithkline Biologicals Sa Composición inmunógena para uso en vacunación contra estafilococos
KR101541383B1 (ko) 2006-03-30 2015-08-03 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
WO2007127339A2 (en) * 2006-04-26 2007-11-08 Tyco Healthcare Group Lp Multi-stage microporation device
SI2445522T1 (sl) 2009-06-22 2017-10-30 Wyeth Llc Imunogeni sestavki antigenov Staphylococcusa aureusa
CA2768204A1 (en) 2009-07-15 2011-01-20 Aimm Therapeutics B.V. Gram-positive bacteria specific binding compounds
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
KR20230031322A (ko) 2020-06-27 2023-03-07 크레센타 바이오사이언시즈 세포 물질대사를 조정하는 화합물의 조성물 및 사용 방법
US12138243B2 (en) 2021-12-31 2024-11-12 Crescenta Biosciences Antiviral use of FABP4 modulating compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3583987D1 (de) 1984-11-06 1991-10-10 Thomae Gmbh Dr K Antibiotisches polypeptid, verfahren zu seiner herstellung und seine verwendung.
ATE95187T1 (de) * 1988-07-15 1993-10-15 Thomae Gmbh Dr K Verfahren zur gewinnung, isolierung und reinigung von epidermin.
US5055455A (en) * 1988-09-28 1991-10-08 Brigham And Women's Hospital Capsular polysaccharide adhesin antigen, preparation, purification and use
US5571511A (en) * 1990-10-22 1996-11-05 The U.S. Government Broadly reactive opsonic antibodies that react with common staphylococcal antigens
EP0621875B1 (en) * 1992-09-21 2002-03-27 Alfa-Laval Agri International Ab Fibrinogen binding protein
IL109410A0 (en) * 1993-04-30 1994-07-31 Ell Lilly & Company Fema gene of staphylococcus epidermidis, fema protein, and vectors and microorganisms comprising the fema gene
US6107068A (en) * 1995-12-22 2000-08-22 The University Of British Columbia Coenzyme A disulfide reductase, and inhibitors thereof useful as antimicrobial agents

Also Published As

Publication number Publication date
ATE316979T1 (de) 2006-02-15
CA2294433A1 (en) 1997-12-24
SE9602496D0 (sv) 1996-06-20
JP2001503609A (ja) 2001-03-21
DE69735207T2 (de) 2006-11-02
US20040209326A1 (en) 2004-10-21
WO1997048727A1 (en) 1997-12-24
EP0922056B1 (en) 2006-02-01
AU3282597A (en) 1998-01-07
US7160990B2 (en) 2007-01-09
US6733758B1 (en) 2004-05-11
ES2258280T3 (es) 2006-08-16
EP0922056A1 (en) 1999-06-16
DE69735207D1 (de) 2006-04-13

Similar Documents

Publication Publication Date Title
JP4173549B2 (ja) コアグラーゼ陰性ブドウ球菌に由来する、新規フィブリノーゲン結合たん白質
AU666329B2 (en) Methods and compositions relating to useful antigens of (moraxella catarrhalis)
EP0397633B1 (en) Fibronectin binding protein as well as its preparation
Meehan et al. Affinity purification and characterization of a fibrinogen-binding protein complex which protects mice against lethal challenge with Streptococcus equi subsp. equi
JPH10191988A (ja) 新規ＧｂｐＡ
Wu et al. Two gene determinants are differentially involved in the biogenesis of Fap1 precursors in Streptococcus parasanguis
JPH06506114A (ja) 新規な遺伝子及びＩｇＡ結合蛋白質の製造方法
Wang et al. Localization of an immunologically functional region of the streptococcal superantigen pepsin-extracted fragment of type 5 M protein.
Kling et al. Characterization of two distinct opsonic and protective epitopes within the alpha C protein of the group B Streptococcus
CA2387392A1 (en) Polypeptide fragments comprising c-terminal portion of helicobacter catalase
Molla et al. Antibodies against synthetic peptides and the topology of LamB, an outer-membrane protein from Escherichia coli K12
HU220101B (hu) Reumás ízületi gyulladás kezelésére szolgáló készítmények
JP2002262891A (ja) スタフィロコッカス・アウレウス由来の２成分シグナルトランスダクションシステムタンパク質
CA2305716A1 (en) Method for assay of wbpm
JPH10201484A (ja) 新規ＦｔｓＬ
JPH10327882A (ja) 新規ＬｉｃＢ
JPH11235181A (ja) 新規ｔｉｇ
JP2000500326A (ja) フィブロネクチン結合タンパク質ｂ化合物
AU3433299A (en) Peptides
JP2004510428A (ja) ブドウ球菌由来のフォンビルブラント因子結合性タンパク質
JPH1169982A (ja) 新規Ｄｉｖ１ｂ
JP2002506624A (ja) スタフィロコッカス・アウレウスｓｐｏ０ｊ２：ポリヌクレオチドおよび蛋白
JPH10313882A (ja) ＬｉｃＡ
JPH10290693A (ja) 新規フィブロネクチン結合蛋白化合物
JPH11137261A (ja) ｄｅｆ２

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040614

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040614

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060919

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061211

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070410

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070706

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20071106

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20071228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080422

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20080502

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20080715

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20080814

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110822

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees